PMID- 30747213
OWN - NLM
STAT- MEDLINE
DCOM- 20190306
LR  - 20211204
IS  - 1791-2431 (Electronic)
IS  - 1021-335X (Linking)
VI  - 41
IP  - 3
DP  - 2019 Mar
TI  - Downregulated Kruppel‑like factor 4 expression is associated with the 
      aggressiveness of prostate cancer.
PG  - 1789-1796
LID - 10.3892/or.2019.6975 [doi]
AB  - Kruppel‑like factor 4 (KLF4) is a transcription factor and putative tumor 
      suppressor. However, little is known about its role in the progression of 
      prostate cancer. The aim of the present study was to examine the expression and 
      potential role of KLF4 in prostate cancer. KLF4 and E‑cadherin expression in 60 
      prostate cancer tissues and 60 benign prostatic hyperplasia tissues was 
      characterized by immunohistochemistry. The levels of KLF4 expression in prostate 
      cancer cells were determined by reverse transcription‑quantitative polymerase 
      chain reaction and western blot analysis. LNCaP cells were transduced with 
      lentivirus to induce KLF4 overexpression. The effects of KLF4 overexpression on 
      proliferation, cell cycle and migration were determined by MTT, flow cytometry, 
      wound healing and Transwell migration assays. KLF4 was identified to be primarily 
      expressed in the cytoplasm of non‑tumor prostate tissues. The percentage of KLF4+ 
      tissues among prostate cancer tissues (16.67%) was significantly lower compared 
      with that of non‑tumor tissues (84.67%; P<0.05). Downregulated KLF4 expression 
      was associated with higher stage, positive lymph node metastasis and higher 
      Gleason scores of prostate cancer (all P<0.05). Induction of KLF4 overexpression 
      significantly inhibited the proliferation, wound healing and migration of LNCaP 
      cells and induced their cell cycle arrest at S phase. Furthermore, E‑cadherin 
      expression was downregulated in prostate cancer tissues and KLF4 overexpression 
      enhanced the levels of E‑cadherin expression in LNCaP cells. In conclusion, 
      downregulated KLF4 expression was associated with aggressiveness of prostate 
      cancer, and KLF4 overexpression inhibited the proliferation, wound healing and 
      migration of prostate cancer cells by inducing cell cycle arrest and E‑cadherin 
      expression.
FAU - Zhang, Neng
AU  - Zhang N
AD  - Department of Urology, The Affiliated Hospital of Zunyi Medical College, Zunyi, 
      Guizhou 563003, P.R. China.
FAU - Su, Peng
AU  - Su P
AD  - Department of Urology, The Affiliated Hospital of Zunyi Medical College, Zunyi, 
      Guizhou 563003, P.R. China.
FAU - Li, Xiaoguang
AU  - Li X
AD  - Department of Urology, The Affiliated Hospital of Zunyi Medical College, Zunyi, 
      Guizhou 563003, P.R. China.
FAU - Xi, Jianming
AU  - Xi J
AD  - Department of Urology, The Affiliated Hospital of Zunyi Medical College, Zunyi, 
      Guizhou 563003, P.R. China.
FAU - Li, Xu
AU  - Li X
AD  - Department of Urology, The Affiliated Hospital of Zunyi Medical College, Zunyi, 
      Guizhou 563003, P.R. China.
FAU - Xu, Luo
AU  - Xu L
AD  - Department of Urology, The Affiliated Hospital of Zunyi Medical College, Zunyi, 
      Guizhou 563003, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20190122
PL  - Greece
TA  - Oncol Rep
JT  - Oncology reports
JID - 9422756
RN  - 0 (Cadherins)
RN  - 0 (KLF4 protein, human)
RN  - 0 (Kruppel-Like Factor 4)
RN  - 0 (Kruppel-Like Transcription Factors)
SB  - IM
MH  - Cadherins/genetics
MH  - Cell Cycle/genetics
MH  - Cell Line, Tumor
MH  - Cell Movement/genetics
MH  - Cell Proliferation/genetics
MH  - Down-Regulation/*genetics
MH  - Gene Expression Regulation, Neoplastic/genetics
MH  - Genes, Tumor Suppressor/physiology
MH  - Humans
MH  - Kruppel-Like Factor 4
MH  - Kruppel-Like Transcription Factors/*genetics
MH  - Male
MH  - Neoplasm Grading/methods
MH  - Prostate/pathology
MH  - Prostatic Hyperplasia/genetics/pathology
MH  - Prostatic Neoplasms/*genetics/pathology
EDAT- 2019/02/13 06:00
MHDA- 2019/03/07 06:00
CRDT- 2019/02/13 06:00
PHST- 2018/06/26 00:00 [received]
PHST- 2018/11/22 00:00 [accepted]
PHST- 2019/02/13 06:00 [pubmed]
PHST- 2019/03/07 06:00 [medline]
PHST- 2019/02/13 06:00 [entrez]
AID - 10.3892/or.2019.6975 [doi]
PST - ppublish
SO  - Oncol Rep. 2019 Mar;41(3):1789-1796. doi: 10.3892/or.2019.6975. Epub 2019 Jan 22.